RNAC Q4 2021 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$218M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$30M+150.5% YoY

Gross Profit

$30M100.0% margin

Operating Income

$4M13.6% margin

Net Income

$12M40.9% margin

EPS (Diluted)

$2.96

QoQ Revenue Growth

+22.6%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$32M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$160M

Total Liabilities

$137M

Stockholders' Equity

$23M

Cash & Equivalents

$114M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$30M	$12M	+150.5%
Gross Profit	$30M	$12M	+150.5%
Operating Income	$4M	-$8M	+151.6%
Net Income	$12M	-$15M	+179.2%